US FDA Approves QBiotics Investigational New Drug Application to Initiate Tigilanol Tiglate Soft Tissue Sarcoma Phase II Trial

QBiotics Group Limited has been granted approval of its Investigational New Drug application by the US FDA for lead oncology molecule, tigilanol tiglate.